MCID: MYS003
MIFTS: 73

Myasthenia Gravis

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Myasthenia Gravis

MalaCards integrated aliases for Myasthenia Gravis:

Name: Myasthenia Gravis 53 37 12 72 49 24 50 55 36 28 51 40 41 14 69
Mg 53 24
Autoimmune Myasthenia Gravis 55
Acquired Myasthenia 55

Characteristics:

Orphanet epidemiological data:

55
myasthenia gravis
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe),1-9/100000 (Worldwide),1-9/1000000 (United States),1-5/10000 (Canada),1-9/100000 (Spain),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/100000 (Serbia),1-5/10000 (United States),1-5/10000 (Serbia),1-9/100000 (Italy),1-5/10000 (Austria),1-9/100000 (Australia),1-5/10000 (Italy),1-9/100000 (Taiwan, Province of China),1-5/10000 (Australia),1-9/1000000 (Greece),1-5/10000 (Taiwan, Province of China),1-9/1000000 (Croatia),1-9/100000 (Estonia),1-9/100000 (Greece),1-9/100000 (Croatia),1-9/100000 (Egypt),1-9/1000000 (Worldwide); Age of onset: All ages; Age of death: normal life expectancy;

OMIM:

53
Inheritance:
usually sporadic
1 to 4 % of cases are familial without a simple mendelian pattern
familial predisposition may be due to autoimmunity in general.


Classifications:

Orphanet: 55  
Rare neurological diseases


Summaries for Myasthenia Gravis

NINDS : 50 Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal muscles of the body, which are responsble for breathing and moving parts of the body. In myasthenia gravis, the immune system--which normally protects the body from foreign organisms--mistakenly attacks itself.  Symptoms vary in type and intensity. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Certain muscles that control eye and eyelid movements, facial expression, chewing, talking, and swallowing are often, but not always, involved. The muscles that control breathing and neck and limb movements may also be affected. Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. Normally when impulses travel down the nerve, the nerve endings release a neurotransmitter substance called acetylcholine. In myasthenia gravis, antibodies produced by the body's own immune system block, alter, or destroy the receptors for acetylcholine. The first noticeable symptoms of myasthenia gravis may be weakness of the eye muscles, difficulty in swallowing, or slurred speech. Other symptoms may include blurred or double vision, drooping eyelid(s), and weakness in the arms, hands, fingers, legs, and neck. Myasthenia gravis is not directly inherited nor is it contagious.

MalaCards based summary : Myasthenia Gravis, also known as mg, is related to neuromuscular disease and congenital myasthenic syndrome, and has symptoms including dyspnea, seizures and ophthalmoparesis. An important gene associated with Myasthenia Gravis is AKAP12 (A-Kinase Anchoring Protein 12), and among its related pathways/superpathways are Allograft rejection and Immune response NFAT in immune response. The drugs Azathioprine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include eye, thymus and skeletal muscle, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Genetics Home Reference : 24 Myasthenia gravis is a disorder that causes weakness of the skeletal muscles, which are muscles that the body uses for movement. The weakness most often starts in the muscles around the eyes, causing drooping of the eyelids (ptosis) and difficulty coordinating eye movements, which results in blurred or double vision. In a form of the disorder called ocular myasthenia, the weakness remains confined to the eye muscles. In most people with myasthenia gravis, however, additional muscles in the face and neck are affected. Affected individuals may have unusual facial expressions, difficulty holding up the head, speech impairment (dysarthria), and chewing and swallowing problems (dysphagia) that may lead to choking, gagging, or drooling.

NIH Rare Diseases : 49 Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. Common symptoms include weakness of the muscles that control the eye and eyelid, facial expressions, chewing, talking, and swallowing. Weakness tends to increase during periods of activity and improve after periods of rest. The condition results from a defect in the transmission of nerve impulses to muscles, which is due to the presence of antibodies against acetylcholine. The exact reason this occurs is not known. Some cases have been linked to tumors in the thymus gland. Researchers believe that variations in certain genes may increase a person's risk to develop MG, but other factors likely also play a role. There is no cure for MG at this time, but treatment can significantly improve muscle weakness. Some cases may go into remission temporarily, and muscle weakness may disappear so that medications can be discontinued. Last updated: 2/23/2017

MedlinePlus : 40 Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 72 Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal... more...

Description from OMIM: 254200

Related Diseases for Myasthenia Gravis

Diseases in the Myasthenia Gravis family:

Myasthenia Gravis Congenital Juvenile Myasthenia Gravis
Adult-Onset Myasthenia Gravis

Diseases related to Myasthenia Gravis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 512)
# Related Disease Score Top Affiliating Genes
1 neuromuscular disease 32.9 MUSK RYR1 TTN
2 congenital myasthenic syndrome 32.3 ACHE AGRN CHRNA1 CHRNE MUSK RAPSN
3 multiple pterygium syndrome, escobar variant 32.2 CHRNA1 CHRNE CHRNG RYR1
4 thymoma 32.1 AIRE CTLA4 IL2 RYR1 TTN
5 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.1 AIRE CTLA4 IFNG IL10
6 ptosis 30.7 CHRNE MUSK RYR1
7 thyroiditis 30.7 CTLA4 IFNG IL2
8 aseptic meningitis 30.3 IFNG IL10 TNF
9 transverse myelitis 30.2 IL10 MBP TNF
10 microscopic polyangiitis 30.2 IL10 TNF
11 cytomegalovirus infection 30.0 IFNG IL10 TNF
12 meningitis 30.0 IFNG IL10 TNF
13 postsynaptic congenital myasthenic syndromes 30.0 AGRN CHRNA1 CHRNE MUSK RAPSN
14 mixed connective tissue disease 30.0 IFNG IL10 TNF
15 bronchiolitis obliterans 30.0 IFNG IL10 TNF
16 polyradiculoneuropathy 30.0 IFNG IL10 MBP
17 lymphadenitis 30.0 IFNG IL10 TNF
18 lichen planus 29.9 IFNG IL4 TNF
19 respiratory failure 29.8 IL10 TNF TTN
20 autoimmune addison disease 29.8 AIRE CTLA4
21 candidiasis 29.8 AIRE IFNG IL10
22 lepromatous leprosy 29.7 IFNG IL10 IL2 TNF
23 chronic mucocutaneous candidiasis 29.7 AIRE IFNG IL10
24 conjunctivitis 29.6 IFNG IL2 IL4
25 progressive multifocal leukoencephalopathy 29.6 IL2 MBP TNF
26 poliomyelitis 29.6 IFNG IL10 IL4 TNF
27 toxoplasmosis 29.6 IFNG IL10 IL4 TNF
28 bronchiolitis 29.6 IFNG IL10 IL4 TNF
29 mycobacterium tuberculosis 1 29.5 IFNG IL10 IL4 TNF
30 systemic lupus erythematosus 29.5 CTLA4 IFNG IL10 IL2 IL4 TNF
31 uveitis 29.5 CTLA4 IFNG IL10 IL4 TNF
32 alopecia areata 29.4 AIRE CTLA4 IFNG IL2 TNF
33 tetanus 29.4 IFNG IL10 IL2 IL4
34 hematopoietic stem cell transplantation 29.4 CTLA4 IFNG IL10 IL2 TNF
35 celiac disease 1 29.3 CTLA4 IFNG IL10 IL2 TNF
36 aplastic anemia 29.3 IFNG IL2 IL4 TNF
37 hashimoto thyroiditis 29.3 AIRE CTLA4 IFNG IL2 IL4
38 leprosy 3 29.2 IFNG IL10 IL2 IL4 TNF
39 neuritis 29.2 IFNG IL4 MBP TNF
40 rheumatoid arthritis 29.0 CTLA4 IFNG IL10 IL2 IL4 TNF
41 multiple sclerosis 28.8 CTLA4 IFNG IL10 IL2 IL4 MBP
42 renal cell carcinoma, nonpapillary 28.5 CTLA4 IFNG IL2 IL4
43 autoimmune disease 28.1 AIRE CTLA4 IFNG IL10 IL2 IL4
44 myasthenia gravis congenital 12.5
45 juvenile myasthenia gravis 12.5
46 transient neonatal myasthenia gravis 12.5
47 adult-onset myasthenia gravis 12.4
48 rippling muscle disease with myasthenia gravis 12.4
49 neonatal myasthenia gravis 12.4
50 myasthenia gravis with thymus hyperplasia 12.3

Graphical network of the top 20 diseases related to Myasthenia Gravis:



Diseases related to Myasthenia Gravis

Symptoms & Phenotypes for Myasthenia Gravis

Symptoms via clinical synopsis from OMIM:

53
HEENT:
ptosis
diplopia
dysarthria
facial muscle weakness
difficulty chewing

Immunology:
autoimmunity
thymoma
antibodies to acetylcholine receptor (achr)
association with gm type

Muscle:
proximal limb muscle weakness.

Pulmonary:
ventilatory insufficiency

GI:
dysphagia

Voice:
nasal speech

Endocrine:
thyrotoxicosis

Misc:
childhood or adolescent onset
static or only slowly progressive


Clinical features from OMIM:

254200

Human phenotypes related to Myasthenia Gravis:

55 31 (show all 35)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dyspnea 55 31 frequent (33%) Frequent (79-30%) HP:0002094
2 seizures 55 31 very rare (1%) Very rare (<4-1%) HP:0001250
3 ophthalmoparesis 55 31 frequent (33%) Frequent (79-30%) HP:0000597
4 hyperacusis 55 31 occasional (7.5%) Occasional (29-5%) HP:0010780
5 ptosis 55 31 frequent (33%) Frequent (79-30%) HP:0000508
6 diplopia 55 31 frequent (33%) Frequent (79-30%) HP:0000651
7 dysarthria 55 31 frequent (33%) Frequent (79-30%) HP:0001260
8 dysphagia 55 31 frequent (33%) Frequent (79-30%) HP:0002015
9 hearing impairment 55 31 occasional (7.5%) Occasional (29-5%) HP:0000365
10 acrocyanosis 55 31 very rare (1%) Very rare (<4-1%) HP:0001063
11 hepatitis 55 31 very rare (1%) Very rare (<4-1%) HP:0012115
12 hemolytic anemia 55 31 very rare (1%) Very rare (<4-1%) HP:0001878
13 hashimoto thyroiditis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000872
14 hyperthyroidism 55 31 occasional (7.5%) Occasional (29-5%) HP:0000836
15 paresthesia 55 31 occasional (7.5%) Occasional (29-5%) HP:0003401
16 primary adrenal insufficiency 55 31 occasional (7.5%) Occasional (29-5%) HP:0008207
17 psychosis 55 31 very rare (1%) Very rare (<4-1%) HP:0000709
18 myositis 55 31 frequent (33%) Frequent (79-30%) HP:0100614
19 abnormality of the thymus 55 31 frequent (33%) Frequent (79-30%) HP:0000777
20 bulbar palsy 55 31 frequent (33%) Frequent (79-30%) HP:0001283
21 single fiber emg abnormality 55 31 frequent (33%) Frequent (79-30%) HP:0030006
22 acetylcholine receptor antibody positivity 55 31 frequent (33%) Frequent (79-30%) HP:0030208
23 muscle specific kinase antibody positivity 55 31 frequent (33%) Frequent (79-30%) HP:0030210
24 rheumatoid arthritis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001370
25 systemic lupus erythematosus 55 31 occasional (7.5%) Occasional (29-5%) HP:0002725
26 glycosuria 55 31 occasional (7.5%) Occasional (29-5%) HP:0003076
27 pure red cell aplasia 55 31 very rare (1%) Very rare (<4-1%) HP:0012410
28 muscle weakness 55 Very frequent (99-80%)
29 facial palsy 31 HP:0010628
30 autoimmunity 31 HP:0002960
31 nasal speech 31 HP:0001611
32 thymoma 31 HP:0100522
33 fatigable weakness 31 HP:0003473
34 limb muscle weakness 31 HP:0003690
35 proximal muscle weakness 31 HP:0003701

UMLS symptoms related to Myasthenia Gravis:


sleeplessness, vertigo/dizziness, facial paresis, muscle weakness, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, back pain

GenomeRNAi Phenotypes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.17 TMPO
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.17 TMPO
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 9.17 CHRNA1 RAPSN TMPO
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.17 TMPO
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.17 TMPO

MGI Mouse Phenotypes related to Myasthenia Gravis:

43 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 AGRN CHRNA1 AIRE CHRNE ACHE AKAP12
2 mortality/aging MP:0010768 10.41 AGRN CHRNA1 CHRNE AIRE ACHE AKAP12
3 homeostasis/metabolism MP:0005376 10.39 AGRN AIRE ACHE IFNG CHRNG CTLA4
4 growth/size/body region MP:0005378 10.38 AGRN CHRNE AIRE ACHE IL10 IFNG
5 hematopoietic system MP:0005397 10.26 AKAP12 AIRE ACHE CTLA4 IL10 IFNG
6 nervous system MP:0003631 10.25 AGRN CHRNA1 AIRE CHRNE ACHE AKAP12
7 digestive/alimentary MP:0005381 10.21 AIRE IL10 IFNG CTLA4 IL4 RYR1
8 muscle MP:0005369 10.21 AGRN CHRNE ACHE AKAP12 IFNG CHRNG
9 endocrine/exocrine gland MP:0005379 10.2 AKAP12 AIRE CTLA4 IL10 IFNG IL4
10 integument MP:0010771 10.15 IL10 IFNG CHRNG CTLA4 IL4 RYR1
11 craniofacial MP:0005382 10.11 ACHE IL10 IFNG IL4 RYR1 TTN
12 liver/biliary system MP:0005370 10.08 AIRE AKAP12 IL10 IFNG CTLA4 IL4
13 respiratory system MP:0005388 10.03 AGRN CHRNE AIRE CHRNG ACHE AKAP12
14 no phenotypic analysis MP:0003012 9.97 CHRNE AIRE ACHE IL10 IFNG IL4
15 normal MP:0002873 9.97 AGRN AIRE AKAP12 CTLA4 IL10 IFNG
16 reproductive system MP:0005389 9.91 AKAP12 AIRE ACHE IL10 IFNG IL4
17 skeleton MP:0005390 9.61 CHRNA1 CTLA4 IL10 IFNG MUSK IL4
18 vision/eye MP:0005391 9.28 AIRE ACHE IL10 IFNG IL4 MBP

Drugs & Therapeutics for Myasthenia Gravis

Drugs for Myasthenia Gravis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
2
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
3 Antimetabolites Phase 4,Phase 3,Phase 2
4 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
5 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
7 Anti-Inflammatory Agents Phase 4,Phase 3
8 Antineoplastic Agents, Hormonal Phase 4,Phase 3
9 glucocorticoids Phase 4,Phase 3
10 Hormone Antagonists Phase 4,Phase 3,Phase 2
11 Hormones Phase 4,Phase 3,Phase 2
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
13 Antibodies Phase 4,Phase 3,Phase 2
14 gamma-Globulins Phase 4,Phase 3,Phase 2
15 Immunoglobulins Phase 4,Phase 3,Phase 2
16 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2
17 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2
18
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
19
Mycophenolic acid Approved Phase 3 24280-93-1 446541
20
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492
21
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
22
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
23
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
24
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
25
4-Aminopyridine Approved Phase 3 504-24-5 1727
26
Rocuronium Approved Phase 3 119302-91-9, 143558-00-3 441290
27
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
28
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
29
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3,Phase 1 21645-51-2
30 tannic acid Approved, Nutraceutical Phase 3
31 Anti-Bacterial Agents Phase 3
32 Antibiotics, Antitubercular Phase 3
33 Anti-Infective Agents Phase 3,Phase 2
34 Antitubercular Agents Phase 3
35 Vaccines Phase 3,Phase 1,Phase 2
36 Calcineurin Inhibitors Phase 3
37 Methylprednisolone acetate Phase 3
38 Methylprednisolone Hemisuccinate Phase 3
39 Prednisolone acetate Phase 3
40 Prednisolone hemisuccinate Phase 3
41 Prednisolone phosphate Phase 3
42 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
43 3,4-diaminopyridine Phase 3
44 Potassium Channel Blockers Phase 3
45 Neuromuscular Agents Phase 3
46 Neuromuscular Blocking Agents Phase 3
47 Neuromuscular Nondepolarizing Agents Phase 3
48 Peripheral Nervous System Agents Phase 3
49 Cholinergic Agents Phase 3,Phase 1,Phase 2
50 Cholinesterase Inhibitors Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 75)

# Name Status NCT ID Phase Drugs
1 Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis Completed NCT00987116 Phase 4 Prednisone - Azathioprine
2 Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis Completed NCT01179893 Phase 4
3 Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) Completed NCT01997229 Phase 3 Placebo
4 A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis Completed NCT01325571 Phase 3 Tacrolimus capsule;Placebo
5 Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis Completed NCT00306033 Phase 3 Intravenous ImmuneGlobulin
6 Mycophenolate Mofetil in Myasthenia Gravis Completed NCT00285350 Phase 3 mycophenolate mofetil
7 Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis Completed NCT00515450 Phase 3
8 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Completed NCT00294658 Phase 3 prednisone alone
9 FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients Completed NCT00309088 Phase 3 tacrolimus;placebo
10 A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis. Completed NCT00408213 Phase 3 mycophenolate mofetil [CellCept];Placebo
11 A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis Completed NCT00683969 Phase 3 mycophenolate mofetil (CellCept);placebo
12 An Open Study for Steroid Resistant, Non-Thymectomized MG Patients Completed NCT00309101 Phase 3 tacrolimus
13 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Completed NCT01377922 Phase 3 Amifampridine Phosphate;Placebo
14 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Completed NCT02970162 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
15 Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest Completed NCT01719770 Phase 3 rocuronium
16 A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis Recruiting NCT02950155 Phase 3 Rituximab;Sodium Chloride solution
17 The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Recruiting NCT01727193 Phase 3 Azathioprine;Leflunomide
18 A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations Recruiting NCT02413580 Phase 3
19 A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Recruiting NCT02774239 Phase 3 Human normal immunoglobulin G (IgG)
20 ECU-MG-302: An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis Active, not recruiting NCT02301624 Phase 3
21 A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis Not yet recruiting NCT03165435 Phase 2, Phase 3
22 Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Not yet recruiting NCT03304054 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
23 Efficacy of Prednisone In the Treatment of Ocular Myasthenia Terminated NCT00995722 Phase 3 Prednisone;Placebo
24 Sulfamethoxazole for the Treatment of Primary PREPL Deficiency Unknown status NCT02640443 Phase 2 Sulfamethoxazole
25 Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis Completed NCT02565576 Phase 2 Placebo;CFZ533
26 Efficacy of Methotrexate in Myasthenia Gravis Completed NCT00814138 Phase 2 Methotrexate
27 A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Completed NCT02965573 Phase 2 Placebo
28 A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis Completed NCT02473952 Phase 2 IGIV-C;Placebo
29 A Pilot Trial of Rituxan in Refractory Myasthenia Gravis Completed NCT00619671 Phase 1, Phase 2 Rituximab (Rituxan)
30 The Evaluation of Belimumab in Myasthenia Gravis (MG) Completed NCT01480596 Phase 2
31 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
32 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
33 Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis. Recruiting NCT03052751 Phase 2 UCB7665
34 Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis Recruiting NCT03315130 Phase 2 RA101495;Placebo
35 Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis Recruiting NCT02473965 Phase 2 IGIV-C;Placebo
36 The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor Recruiting NCT02317224 Phase 2
37 Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Recruiting NCT02102594 Phase 2 Bortezomib
38 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure Recruiting NCT03174964 Phase 2 IVIg
39 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss Recruiting NCT03174951 Phase 2 IVIg
40 BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis Active, not recruiting NCT02110706 Phase 2 Rituximab;Placebo
41 Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis Active, not recruiting NCT02609022 Phase 1, Phase 2
42 Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis Active, not recruiting NCT02100969 Phase 2 HIZENTRA ®
43 Pyridostigmine as Immunomodulator in People Living With HIV Active, not recruiting NCT03312244 Phase 2 Pyridostigmine Bromide;Placebo
44 Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Terminated NCT00727194 Phase 2 eculizumab;Placebo
45 Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis Terminated NCT01268280 Phase 2 Placebo;250 mg CK-2017357;500 mg CK-2017357
46 Exercise for Stable Myasthenia Gravis Recruiting NCT01047761 Phase 1
47 Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis Terminated NCT00424489 Phase 1
48 A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis Unknown status NCT01555580 Early Phase 1 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
49 Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis Unknown status NCT00997412 Mycophenolic acid;AZA
50 The Effect of Erythromycin on Occurrence of Leaks From Cervical Esophageal-Gastric Anastomosis After Trans-Hiatal Esophagectomy Unknown status NCT00373919 intravenous (IV) administration of erythromycin

Search NIH Clinical Center for Myasthenia Gravis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myasthenia Gravis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myasthenia Gravis:
Hematopoietic stem cells for refractory myasthenia gravis
Embryonic/Adult Cultured Cells Related to Myasthenia Gravis:
Peripheral blood-derived hematopoietic stem cells

Cochrane evidence based reviews: myasthenia gravis

Genetic Tests for Myasthenia Gravis

Genetic tests related to Myasthenia Gravis:

# Genetic test Affiliating Genes
1 Myasthenia Gravis 28

Anatomical Context for Myasthenia Gravis

MalaCards organs/tissues related to Myasthenia Gravis:

38
Eye, Thymus, Skeletal Muscle, Testes, T Cells, B Cells, Thyroid

Publications for Myasthenia Gravis

Articles related to Myasthenia Gravis:

(show top 50) (show all 1511)
# Title Authors Year
1
A Well-Tolerated and Effective Antiepileptic Drug for Patients With Myasthenia Gravis at Last? ( 29432285 )
2018
2
Dysphagia in myasthenia gravis: the tip of the Iceberg. ( 29417423 )
2018
3
Whole-exome sequencing reveals a rare interferon gamma receptor 1 mutation associated with myasthenia gravis. ( 29441481 )
2018
4
When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. ( 29403543 )
2018
5
Relapsed Myasthenia Gravis after Nivolumab Treatment. ( 29434145 )
2018
6
Introducing Autoimmunity at the Synapse by a Novel Animal Model of Experimental Autoimmune Myasthenia Gravis. ( 29421431 )
2018
7
Thymus imaging in myasthenia gravis - the relevance in clinical practice. ( 29424940 )
2018
8
Open source modular ptosis crutch for the treatment of myasthenia gravis. ( 29271663 )
2018
9
Occipitalis muscle: using for repetitive facial nerve stimulation in myasthenia gravis. ( 29428994 )
2018
10
Prognosis of Ocular Myasthenia Gravis in an Argentinian Population. ( 29428956 )
2018
11
An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients. ( 29405352 )
2018
12
Characteristics, incidence, and outcome of patients admitted to the intensive care unit with myasthenia gravis. ( 29413729 )
2018
13
3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome. ( 29402568 )
2018
14
Muscle strength and psychiatric symptoms influence health-related quality of life in patients with myasthenia gravis. ( 29396072 )
2018
15
Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy. ( 29395322 )
2018
16
Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis. ( 29414833 )
2018
17
Eculizumab: A Review in Generalized Myasthenia Gravis. ( 29435915 )
2018
18
The thymidylate synthase enhancer region (TSER) polymorphism increases the risk of thymic lymphoid hyperplasia in patients with Myasthenia Gravis. ( 29162511 )
2018
19
Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy. ( 29269644 )
2018
20
A quantitative method for the assessment of dysarthrophonia in myasthenia gravis. ( 28477705 )
2017
21
Clinical and pathological aspects of microscopic thymoma with myasthenia gravis and review of published reports. ( 28740673 )
2017
22
Transient neonatal myasthenia gravis with infantile hypertrophic pyloric stenosis: coincidence or causation? ( 29099348 )
2017
23
Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis. ( 28075449 )
2017
24
Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis. ( 28921038 )
2017
25
Myasthenia gravis and chronic inflammatory demyelinating polyneuropathy in the same patientA -A a case report. ( 29073825 )
2017
26
B cells in the pathophysiology of myasthenia gravis. ( 28940642 )
2017
27
Ophthalmoplegia due to concurrent thyrotoxicosis and myasthenia gravis. ( 29398296 )
2017
28
Different neurologic outcomes of myasthenia gravis with thymic hyperplasia and thymoma after extended thymectomy: A single center experience. ( 29246632 )
2017
29
Pathological Findings in Myasthenia Gravis Patients with Thymic Hyperplasia and Thymoma. ( 28299711 )
2017
30
Take a deep breath but don't relax: Anesthesia for thymectomy in myasthenia gravis. ( 29409614 )
2017
31
Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. ( 28878127 )
2017
32
VATS thymectomy for early stage thymoma and myasthenia gravis: combined right-sided uniportal and left-sided three-portal approach. ( 29302420 )
2017
33
Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. ( 28516329 )
2017
34
Analysis of mortality and related factors in 2195 adult myasthenia gravis patients in a 10-year follow-up study. ( 28488612 )
2017
35
Thymectomy and myasthenia gravis: A history of surgical passion and scientific excellence. ( 28479053 )
2017
36
Ocular Presentation of Myasthenia Gravis: A Natural History Cohort. ( 28881457 )
2017
37
Frame-shift variant in the CHRNE gene in a juvenile dog with suspected myasthenia gravis-like disease. ( 28508416 )
2017
38
Juvenile myasthenia gravis in Norway: HLA-DRB1*04:04 is positively associated with prepubertal onset. ( 29036181 )
2017
39
Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis. ( 28933591 )
2017
40
The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review. ( 28401300 )
2017
41
Pyridostigmine-Induced Bradycardia in Patient With MuSK-Ab-Positive Myasthenia Gravis and Alopecia Universalis. ( 28827491 )
2017
42
Acupuncture for Management of Type 2 Diabetes Mellitus in a Patient with Myasthenia Gravis: A Case Report. ( 28889846 )
2017
43
Randomized Trial of Thymectomy in Myasthenia Gravis. ( 28471717 )
2017
44
Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing. ( 28087666 )
2017
45
IFNA-AS1 regulates CD4+ T cell activation in myasthenia gravis though HLA-DRB1. ( 28822831 )
2017
46
Negative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravis. ( 28488158 )
2017
47
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. ( 28821685 )
2017
48
Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel. ( 28495138 )
2017
49
Distinguishing Features of the Repetitive Nerve Stimulation Test Between Lambert-Eaton Myasthenic Syndrome and Myasthenia Gravis, 50-Year Reappraisal. ( 29189551 )
2017
50
Safe Use of Atypical Antipsychotics in a Patient With Postpartum Psychosis and a History of Seronegative Myasthenia Gravis. ( 28703945 )
2017

Variations for Myasthenia Gravis

Expression for Myasthenia Gravis

Search GEO for disease gene expression data for Myasthenia Gravis.

Pathways for Myasthenia Gravis

Pathways related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.79 CTLA4 IFNG IL10 IL2 IL4 TNF
2
Show member pathways
12.6 IFNG IL10 IL2 IL4 TNF
3
Show member pathways
12.53 IFNG IL10 IL2 IL4 TNF
4 12.51 CTLA4 IFNG IL10 IL2 IL4 TNF
5
Show member pathways
12.32 CTLA4 IFNG IL10 IL2 IL4 TNF
6
Show member pathways
12.31 IFNG IL10 IL2 IL4
7
Show member pathways
12.29 IFNG IL2 IL4 TNF
8
Show member pathways
12.21 IFNG IL10 IL4 TNF
9
Show member pathways
12.08 IFNG IL10 IL2 IL4 TNF
10
Show member pathways
11.88 IFNG IL10 IL2 TNF
11 11.88 IFNG IL2 IL4 MBP TNF
12 11.83 IFNG IL10 TNF
13 11.83 IFNG IL10 IL2 IL4 TNF
14 11.8 CTLA4 IFNG TNF
15
Show member pathways
11.77 CHRNA1 CHRNE CHRNG
16 11.75 IFNG IL2 IL4
17 11.72 IFNG IL10 IL2 TNF
18 11.66 CTLA4 IL10 IL4 TNF
19
Show member pathways
11.63 IFNG IL2 TNF
20
Show member pathways
11.61 IFNG IL2 TNF
21 11.54 AGRN CHRNA1 MUSK RAPSN
22 11.51 IFNG IL2 TNF
23 11.48 IL10 IL4 TNF
24 11.48 IFNG IL10 TNF
25 11.46 IFNG IL2 TNF
26 11.46 IFNG IL10 IL2 IL4 TNF
27 11.42 IFNG IL10 IL2 IL4
28 11.31 IFNG IL10 TNF
29 11.28 IFNG IL2 IL4
30 11.25 IFNG IL4 TNF
31
Show member pathways
11.23 CTLA4 IFNG IL2 IL4 TNF
32
Show member pathways
11.18 IFNG IL10 IL2 TNF
33 11.16 IL10 IL2 IL4 TNF
34 10.97 IFNG IL10 IL2 IL4
35 10.77 CHRNA1 CHRNE RYR1
36 10.5 IFNG IL10 IL2 IL4 TNF

GO Terms for Myasthenia Gravis

Cellular components related to Myasthenia Gravis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.87 ACHE AGRN CHRNA1 CHRNE CHRNG MUSK
2 postsynaptic membrane GO:0045211 9.65 CHRNA1 CHRNE CHRNG MUSK RAPSN
3 acetylcholine-gated channel complex GO:0005892 9.33 CHRNA1 CHRNE CHRNG
4 neuromuscular junction GO:0031594 9.26 ACHE CHRNA1 MUSK RAPSN
5 synapse GO:0045202 9.17 ACHE AGRN CHRNA1 CHRNE CHRNG MUSK

Biological processes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.99 IFNG IL10 IL2 IL4 TNF
2 positive regulation of protein phosphorylation GO:0001934 9.81 IFNG IL2 MUSK TNF
3 excitatory postsynaptic potential GO:0060079 9.78 CHRNA1 CHRNE CHRNG
4 humoral immune response GO:0006959 9.73 AIRE IFNG TNF
5 regulation of postsynaptic membrane potential GO:0060078 9.67 CHRNA1 CHRNE CHRNG
6 muscle contraction GO:0006936 9.67 CHRNE CHRNG RYR1 TTN
7 response to nicotine GO:0035094 9.63 CHRNA1 CHRNE CHRNG
8 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL10 TNF
9 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.6 IL10 MBP
10 skeletal muscle acetylcholine-gated channel clustering GO:0071340 9.58 MUSK RAPSN
11 positive regulation of isotype switching to IgG isotypes GO:0048304 9.58 IL2 IL4
12 endothelial cell apoptotic process GO:0072577 9.57 IL10 TNF
13 positive regulation of MHC class II biosynthetic process GO:0045348 9.55 IL10 IL4
14 negative regulation of cytokine secretion involved in immune response GO:0002740 9.54 IL10 TNF
15 type 2 immune response GO:0042092 9.52 IL10 IL4
16 neuromuscular synaptic transmission GO:0007274 9.5 CHRNA1 CHRNE CHRNG
17 regulation of isotype switching GO:0045191 9.48 IL10 IL4
18 receptor biosynthetic process GO:0032800 9.43 IL10 TNF
19 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.4 IFNG TNF
20 regulation of regulatory T cell differentiation GO:0045589 9.33 CTLA4 IFNG IL2
21 positive regulation of vitamin D biosynthetic process GO:0060557 9.26 IFNG TNF
22 synaptic transmission, cholinergic GO:0007271 9.26 CHRNA1 CHRNE CHRNG RAPSN
23 immune response GO:0006955 9.23 AIRE CTLA4 IFNG IL10 IL2 IL4

Molecular functions related to Myasthenia Gravis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.65 IFNG IL10 IL2 IL4 TNF
2 protease binding GO:0002020 9.62 MBP RYR1 TNF TTN
3 extracellular ligand-gated ion channel activity GO:0005230 9.58 CHRNA1 CHRNE CHRNG
4 ligand-gated ion channel activity GO:0015276 9.54 CHRNA1 CHRNE CHRNG
5 acetylcholine-gated cation-selective channel activity GO:0022848 9.33 CHRNA1 CHRNE CHRNG
6 acetylcholine receptor activity GO:0015464 9.13 CHRNA1 CHRNE CHRNG
7 acetylcholine binding GO:0042166 8.92 ACHE CHRNA1 CHRNE CHRNG

Sources for Myasthenia Gravis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....